CytomX Therapeutics Inc (CTMX) - Total Liabilities
Based on the latest financial reports, CytomX Therapeutics Inc (CTMX) has total liabilities worth $50.87 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CTMX cash flow metrics to assess how effectively this company generates cash.
CytomX Therapeutics Inc - Total Liabilities Trend (2013–2024)
This chart illustrates how CytomX Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check CytomX Therapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
CytomX Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of CytomX Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pentamaster Corporation Bhd
KLSE:7160
|
Malaysia | RM195.33 Million |
|
Lsb Industries Inc
NYSE:LXU
|
USA | $644.94 Million |
|
Surge Energy Inc.
TO:SGY
|
Canada | CA$599.53 Million |
|
Scanfil Oyj
HE:SCANFL
|
Finland | €247.30 Million |
|
NioCorp Developments Ltd. Common Stock
NASDAQ:NB
|
USA | $39.97 Million |
|
Shenzhen Xfh Technology Co Ltd
SHE:300890
|
China | CN¥2.65 Billion |
|
Xingtong Shipping Co. Ltd.
SHG:603209
|
China | CN¥1.89 Billion |
|
Bright Minds Biosciences Inc
NASDAQ:DRUG
|
USA | $1.60 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down CytomX Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CTMX stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CytomX Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CytomX Therapeutics Inc (2013–2024)
The table below shows the annual total liabilities of CytomX Therapeutics Inc from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $120.99 Million | -51.46% |
| 2023-12-31 | $249.24 Million | -28.10% |
| 2022-12-31 | $346.64 Million | +38.64% |
| 2021-12-31 | $250.03 Million | -31.77% |
| 2020-12-31 | $366.44 Million | +26.28% |
| 2019-12-31 | $290.17 Million | -11.05% |
| 2018-12-31 | $326.23 Million | -0.46% |
| 2017-12-31 | $327.75 Million | +171.65% |
| 2016-12-31 | $120.65 Million | +69.58% |
| 2015-12-31 | $71.15 Million | -53.07% |
| 2014-12-31 | $151.60 Million | +159.32% |
| 2013-12-31 | $58.46 Million | -- |
About CytomX Therapeutics Inc
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic w… Read more